肝动脉化疗栓塞联合微波消融治疗原发性巨块型肝癌的疗效

【目的】探讨经肝动脉化疗栓塞术（TACE）联合经皮微波消融（PMCT ）治疗原发性巨块型肝癌的临床疗效及安全性。【方法】将60例原发性巨块型肝癌患者随机分为对照组和观察组，其中对照组28例，仅行TACE治疗；观察组32例，先行TACE治疗，2周后再行PMCT治疗。比较分析两组治疗后的近期疗效及平均生存时间。【结果】对照组患者1、2年生存率分别为643．％（18／28）、429．％（12／28），平均生存时间（161．±32．）个月。观察组患者1、2年生存率分别为813．％（26／32）、563．％（18／32），平均生存时间（227．±47．）个月，两组生存率、平均生存时间比较差异均有显著性（ P ＜00．5）。两组耐受性均良好，不良反应发生率相比较差异无显著性（ P ＞00．5）。两组均无严重并发症。【结论】 TACE联合PMCT 治疗原发性巨块型肝癌疗效好，不良反应轻微，值得临床推广应用。

Clinical Application of Hepatic Arterial Chemoembolization Combined with Percutaneous Mi-crowave Coagulation Therapy for Primary Massive Liver Cancer

[Objective] To evaluate the clinical efficacy and side effects of hepatic arterial chemoemboliza‐tion (TACE) combined with percutaneous microwave coagulation therapy (PMCT) for primary massive liver cancer .[Methods] Sixty patients with primary massive liver cancer were randomly divided into two groups ,in which 28 cases of the control group (TACE group) received only TACE treatment and 32 cases of the observa‐tion group (combined treatment group) received microwave ablation two weeks after TACE treatment .[Re‐sults] In the TACE group ,one‐and two‐year survival rates were 64 3.% (18/28) and 42 9.% (12/28) ,respec‐tively ;the mean survival time was (16 1. ± 3 2.) months .In the combined treatment group ,one‐and two‐year survival rates were 81 3.% (26/32) and 56 3.% (18/32) ,respectively ;the mean survival time was (22 7. ± 4 7.) months .The two groups showed significant difference in survival rate and median survival time ( P <0 0.5) , but the two groups showed no significant differences in incidence rate of side effects ( P >0 0.5) .Moreover , patients in both of two groups had good tolerance and slight complications[.Conclusion] TACE combined with PMCT has good efficacy and slight side effect ;it is worthy of being further studied and popularized .